CSF3 and breast carcinoma: However, primary prevention through the use of granulocyte colony-stimulating factors (G-CSF) is not commonly recommended in protocols for the management of breast cancer in the United Kingdom, and a significant proportion of patients undergoing chemotherapy for breast cancer go on to develop febrile neutropenia (Leonard et al, 2003), making its management an important consideration.